University of Iowa
Nuclear factor-kappa B blockade encourages neuroblastoma destruction
Published in Elder Law Weekly, December 1st, 2004
"Neuroblastoma is the most common solid extracranial neoplasm in children and causes many deaths. Despite treatment advances, prognosis for neuroblastoma remains poor, and a critical need exists for the development of new treatment regimens. Tumor necrosis factor (TNF)-related apoptosis-inducing-ligand (TRAIL) induces cell death in a variety of tumors, but not in normal tissues," investigators in the United States report.
"Moreover, TRAIL is nontoxic, making it a strong antitumor therapeutic candidate. We demonstrate that introduction of the TRAIL gene into neuroblastoma cell lines...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
Source: Elder Law Weekly (2004-12-01)
More Articles from Elder Law Weekly
- Centocor
New reimbursement policy increases patient access to REMICADE - Neurobiological Technologies, Inc.
Biotechnology company receives royalty payment for Alzheimer product - Novartis
Femara gets U.S. FDA nod as post-tamoxifen treatment for early breast cancer - Pontificia Universidad Catolica de Chile
Beta-sheet breaker peptide prevents Alzheimer's memory impairments - UMR 6186, Marseille
Effects of chronic L-DOPA treatment elucidated - Adolor Corporation
Biopharmaceutical company reports loss of $0.22 per share - More from this issue of Elder Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
